Additional oral food challenge considerations - 06/06/18
Doi : 10.1016/j.jaci.2018.02.037
J. Andrew Bird, MD a 
, David M. Fleischer, MD b, Marion Groetch, MS, RDN c, Anna Nowak-Węgrzyn, MD c, Scott Sicherer, MD c, Michael C. Young, MD d
, David M. Fleischer, MD b, Marion Groetch, MS, RDN c, Anna Nowak-Węgrzyn, MD c, Scott Sicherer, MD c, Michael C. Young, MD d a University of Texas Southwestern Medical School, Dallas, Tex
b University of Colorado Denver School of Medicine and Children's Hospital Colorado, Aurora, Colo
c Icahn School of Medicine at Mount Sinai, New York, NY
d Boston Children's Hospital, Harvard Medical School, Boston, Mass
Le texte complet de cet article est disponible en PDF.
| Disclosure of potential conflict of interest: J. A. Bird has received personal fees from Food Allergy Research and Education, Aimmune Therapeutics, and DBV Technologies, and has received grants from Aimmune Therapeutics and DBV Technologies. D. M. Fleischer has received travel support from the American College of Allergy, Asthma, and Immunology and Nestle Nutrition; is on the scientific advisory council for the National Peanut Board; serves on the FAACT Medical Advisory Board and FARE Clinical Advisory Board; has consultant arrangements with DBV Technologies, Aimmune Therapeutics, Monsanto, Kaleo Pharma, INSYS Therapeutics, and BEFORE Brands; is employed by University of Colorado Medicine; has received grants from Nestle Nutrition Institute, DBV Technologies, and Aimmune Therapeutics; has received payment for lectures from Nestle Nutrition Institute and the American College of Allergy, Asthma, and Immunology; has received payment for manuscript preparation from the Nestle Nutrition Institute; and has received royalties from UpToDate. M. Groetch has received personal fees from Nutricia North America and Mead Johnson. A. Nowak-Węgrzyn has received grants from the National Institutes of Health/National Institute of Allergy and Infectious Diseases, DBV Technologies, Astellas Pharma, Nutricia, Nestle, and Thermo Fisher, and has received personal fees from Nutricia, Nestle, Thermofisher, Merck, and UpToDate. S. Sicherer has received personal fees from UpToDate, Johns Hopkins University Press, and the American Academy of Allergy, Asthma & Immunology and has received grants from the National Institutes of Health/National Institute of Allergy and Infectious Diseases and HAL Allergy. M. C. Young declares no relevant conflicts of interest. |
© 2018
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 141 - N° 6
P. 2322 - juin 2018 Retour au numéro
Article précédent
- Non-posttransplant lymphoproliferative disorder malignancy after hematopoietic stem cell transplantation in patients with primary immunodeficiency: UK experience
- Mohamed Najib Mohamed Unni, Reem Elfeky, Kanchan Rao, Zohreh Nademi, Robert Chiesa, Persis Amrolia, Roderick Skinner, Olga Slater, Austen Worth, Terence Flood, Mario Abinun, Sophie Hambleton, Waseem Qasim, Hubert B. Gaspar, Andrew J. Cant, Andrew R. Gennery, Paul Veys, Mary A. Slatter
- Reply
- Barbara K. Ballmer-Weber, Kirsten Beyer
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?